Table 1.
Baseline Demographic and Smoking Characteristics by Intervention Group
| INTERVENTION GROUP | |||||
|---|---|---|---|---|---|
| Total (n = 32) |
Patch (n = 11) |
Varenicline (n = 10) |
Placebo (n = 11) |
p = | |
| Age | 42.9 (± 9.7) | 39.1 (± 9.1) | 45.7 (± 12.7) | 44.2 (± 6.1) | .382a |
| n (%) Male | 15 (46.9%) | 6 (54.5%) | 4 (40.0%) | 5 (45.5%) | .905b |
| Cigs / Day | 7.6 (± 2.4) | 8.6 (± 1.2) | 7.4 (± 3.1) | 6.9 (± 2.4) | .268a |
| Age Regular Smoking | 19.3 (± 5.4) | 20.3 (± 8.1) | 18.8 (± 3.8) | 18.6 (± 2.6) | .855a |
| FTND | 2.9 (± 1.8) | 3.6 (± 1.7) | 2.7 (± 1.8) | 2.3 (± 1.7) | .151a |
| Lifetime Quit Attempts | 4.5 (± 4.6) | 3.7 (± 3.4) | 5.3 (± 5.1) | 4.5 (± 5.4) | .855a |
| n (%) Prior NRT Use | 12 (38.7%) c | 5 (45.5%) | 1 (11.1%) c | 6 (54.5%) | .130b |
| n (%) Prior Zyban Use | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1.00b |
| n (%) Prior Chantix Use | 1 (3.2%) c | 0 (0.0%) | 1 (11.1%) c | 0 (0.0%) | .290b |
| # Valid Follow-Ups | 3.9 (± 1.9) | 3.7 (± 1.7) | 4.4 (± 2.0) | 3.7 (± 2.2) | .520a |
| Completed Week 2 F/U | 24 (75.0%) | 8 (72.7%) | 7 (70.0%) | 9 (81.8%) | .884b |
| Completed Month 1 F/U | 18 (56.3%) | 5 (45.5%) | 6 (60.0%) | 7 (63.6%) | .742b |
| Completed Month 2 F/U | 19 (59.4%) | 5 (45.5%) | 8 (80.0%) | 6 (54.6%) | .289b |
| Completed Month 3 F/U | 21 (65.6%) | 7 (63.6%) | 8 (80.0%) | 6 (54.6%) | .580b |
| Completed Month 4 F/U | 21 (65.6%) | 7 (63.6%) | 8 (80.0%) | 6 (54.6%) | .580b |
| Completed Month 6 F/U | 23 (71.9%) | 9 (81.8%) | 7 (70.0%) | 7 (63.6%) | .709b |
a
Comparisons of continuous characteristics were tested with the Kruskal-Wallis equality of populations test for rank-ordered data.
b
Fisher’s exact p.
c
In the placebo group, 1 participant did not complete the assessment which captured prior use of cessation treatments. Therefore, the noted % values correspond to a denominator of 10.